Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 3, 2010, Pages 318-323

  Dembele M ^a   Saleri, N ^a,b   Carvalho, A C C ^b   Saouadogo, T ^a   Hien, A D ^c   Zabsonre, I ^d   Koala, S T ^e   Simpore J ^f   Matteelli, Alberto ^b  

^a MINISTÈRE DE LA SANTÉ   (Burkina Faso)

^b UNIVERSITY OF BRESCIA   (Italy)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d Red Cross Ambulatory for HIV/AIDS Treatment ^*  (Burkina Faso)

^e African Solidarity Association   (Burkina Faso)

^f Centre de Recherche Biomoleculaire Pietro Annigoni CERBA   (Burkina Faso)

Author keywords

HAART; HIV infection; Incidence; Tuberculosis

Indexed keywords

COTRIMOXAZOLE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; BURKINA FASO; CD4+ T LYMPHOCYTE; CELL COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMEAR; TREATMENT DURATION; TUBERCULOSIS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BURKINA FASO; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 77949510124     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. World Health Organization. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009. WHO/HTM/ TB/2009.411. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/publications/global-report/2009/en/index.html Accessed November 2009.
2. Joint United Nations Programme on HIV/AIDS. Report on the global AIDS epidemic 2008. UNAIDS/08.25E / JC1510E. Geneva, Switzerland: UNAIDS 2008. http://www.kui.no/doc/Fakta%20hiv%20aids/JC1510-2008GlobalReport-en.pdf Accessed November 2009.
3. Girardi E, Antonucci G, Vanacore P, et al. Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection. AIDS 2000; 14: 1985-1989.
4. Santoro-Lopes G, Felix de Pinho A M, Harrison L H, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34: 543-546.
5. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence on tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064.
6. Lawn S D, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long-term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116.
7. Lawn S D, Myer L, Bekker L G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612.
8. Seyler C, Toure S, Messou E, Bonard D, Gabillard D, Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 2005; 172: 123-127.
9. Bonnet M M, Pinoges L L, Varaine F F, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20: 1275-1279.
10. Ministère de la Santé, Burkina Faso. Plan d'action du Programme National Tuberculose 2009. Ougadougou, Burkina Faso: Ministère de la Santé, 2009. [French]
11. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach. Geneva, Switzerland: WHO, 2003. http://www.who.int/3by5/publications/documents/ arv-guidelines/en/ Accessed November 2009.
12. Tuberculosis Coalition for Technical Assistance. International standards for tuberculosis care. The Hague, The Netherlands: TBCTA, 2006. http://www.who.int/tb/publications/2006/istc-report.pdf Accessed November 2009.
13. World Health Organization. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance African Region. WHO/HIV/2005.02. Geneva, Switzerland: WHO, 2005. http://www.who.int/hiv/pub/guidelines/ clinicalstaging.pdf Accessed November 2009.
14. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21: 713-719.
15. Moh R, Danel C, Messou E, et al. Incidents and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21: 2483-2491.
16. Seyler C, Messou E, Gabillard D, Inwoley A, Alioum A, A nglaret X. Morbidity before and after HAART initiation in sub-Saharan African HIV-infected adults: a recurrent event analysis. AIDS Res Human Retrovir 2007; 23: 1338-1347.
17. Lawn S D, Wilkinson R J, Lipman M C I, Wood R. Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-685.
18. Coetzee D, Hilderbrand K, Goemaere E, Matthys F, Boelaert M. Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health 2004; 9 (Suppl): A11-A15. [Abstract]